Browse PLD1

Summary
SymbolPLD1
Namephospholipase D1, phosphatidylcholine-specific
Aliases choline phosphatase 1; phosphatidylcholine-hydrolyzing phospholipase D1; hPLD1; PLD 1; Phospholipase D1
Chromosomal Location3q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, perinuclear region Endoplasmic reticulum membrane Lipid-anchor Cytoplasmic side Golgi apparatus membrane Lipid-anchor Cytoplasmic side Late endosome membrane Lipid-anchor Cytoplasmic side
Domain PF00169 PH domain
PF00614 Phospholipase D Active site motif
PF13091 PLD-like domain
PF00787 PX domain
Function

Implicated as a critical step in numerous cellular pathways, including signal transduction, membrane trafficking, and the regulation of mitosis. May be involved in the regulation of perinuclear intravesicular membrane traffic (By similarity).

> Gene Ontology
 
Biological Process GO:0006654 phosphatidic acid biosynthetic process
GO:0007265 Ras protein signal transduction
GO:0016042 lipid catabolic process
GO:0030031 cell projection assembly
GO:0030033 microvillus assembly
GO:0032528 microvillus organization
GO:0032530 regulation of microvillus organization
GO:0032534 regulation of microvillus assembly
GO:0046473 phosphatidic acid metabolic process
GO:0048017 inositol lipid-mediated signaling
GO:0060491 regulation of cell projection assembly
Molecular Function GO:0004620 phospholipase activity
GO:0004630 phospholipase D activity
GO:0005543 phospholipid binding
GO:0008081 phosphoric diester hydrolase activity
GO:0016298 lipase activity
GO:0035091 phosphatidylinositol binding
GO:0042578 phosphoric ester hydrolase activity
GO:0070290 N-acylphosphatidylethanolamine-specific phospholipase D activity
Cellular Component GO:0005765 lysosomal membrane
GO:0005770 late endosome
GO:0010008 endosome membrane
GO:0016324 apical plasma membrane
GO:0030139 endocytic vesicle
GO:0031902 late endosome membrane
GO:0044440 endosomal part
GO:0045177 apical part of cell
GO:0098852 lytic vacuole membrane
> KEGG and Reactome Pathway
 
KEGG hsa04014 Ras signaling pathway
hsa04024 cAMP signaling pathway
hsa04071 Sphingolipid signaling pathway
hsa04144 Endocytosis
hsa04666 Fc gamma R-mediated phagocytosis
hsa04724 Glutamatergic synapse
hsa04912 GnRH signaling pathway
hsa00564 Glycerophospholipid metabolism
hsa00565 Ether lipid metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis
R-HSA-1483206: Glycerophospholipid biosynthesis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-6798695: Neutrophil degranulation
R-HSA-1483257: Phospholipid metabolism
R-HSA-2029485: Role of phospholipids in phagocytosis
R-HSA-1483166: Synthesis of PA
R-HSA-1483148: Synthesis of PG
Summary
SymbolPLD1
Namephospholipase D1, phosphatidylcholine-specific
Aliases choline phosphatase 1; phosphatidylcholine-hydrolyzing phospholipase D1; hPLD1; PLD 1; Phospholipase D1
Chromosomal Location3q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PLD1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PLD1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23804711Chronic Lymphocytic LeukemiaPromote immunityTransendothelial migration (TEM) of normal lymphocytes into lymph nodes requires the chemokine-induced activation of Rap1 and αLβ2 integrin. However, in most cases of CLL, Rap1 is refractory to chemokine stimulation, resulting in failed αLβ2 activation and TEM unless α4β1 is coexpressed. In this study, we show that the inability of CXCL12 to induce Rap1 GTP loading in CLL cells results from failure of Rap1-containing endosomes to translocate to the plasma membrane. Taken together, our findings indicate that chemokine unresponsiveness in CLL lymphocytes results from failure of Arf1/phospholipase D1-mediated translocation of Rap1 to the plasma membrane for GTP loading and may be a specific feature of anergy induced by DNA Ags.
Summary
SymbolPLD1
Namephospholipase D1, phosphatidylcholine-specific
Aliases choline phosphatase 1; phosphatidylcholine-hydrolyzing phospholipase D1; hPLD1; PLD 1; Phospholipase D1
Chromosomal Location3q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PLD1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPLD1
Namephospholipase D1, phosphatidylcholine-specific
Aliases choline phosphatase 1; phosphatidylcholine-hydrolyzing phospholipase D1; hPLD1; PLD 1; Phospholipase D1
Chromosomal Location3q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PLD1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.6280.112
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.2320.337
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1960.822
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4050.152
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.8030.637
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0990.964
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2440.602
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5730.679
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1110.942
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.350.731
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9660.516
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3010.00971
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PLD1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPLD1
Namephospholipase D1, phosphatidylcholine-specific
Aliases choline phosphatase 1; phosphatidylcholine-hydrolyzing phospholipase D1; hPLD1; PLD 1; Phospholipase D1
Chromosomal Location3q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PLD1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPLD1
Namephospholipase D1, phosphatidylcholine-specific
Aliases choline phosphatase 1; phosphatidylcholine-hydrolyzing phospholipase D1; hPLD1; PLD 1; Phospholipase D1
Chromosomal Location3q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PLD1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PLD1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPLD1
Namephospholipase D1, phosphatidylcholine-specific
Aliases choline phosphatase 1; phosphatidylcholine-hydrolyzing phospholipase D1; hPLD1; PLD 1; Phospholipase D1
Chromosomal Location3q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PLD1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPLD1
Namephospholipase D1, phosphatidylcholine-specific
Aliases choline phosphatase 1; phosphatidylcholine-hydrolyzing phospholipase D1; hPLD1; PLD 1; Phospholipase D1
Chromosomal Location3q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PLD1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPLD1
Namephospholipase D1, phosphatidylcholine-specific
Aliases choline phosphatase 1; phosphatidylcholine-hydrolyzing phospholipase D1; hPLD1; PLD 1; Phospholipase D1
Chromosomal Location3q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PLD1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPLD1
Namephospholipase D1, phosphatidylcholine-specific
Aliases choline phosphatase 1; phosphatidylcholine-hydrolyzing phospholipase D1; hPLD1; PLD 1; Phospholipase D1
Chromosomal Location3q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PLD1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PLD1.
ID Name Drug Type Targets #Targets
DB00122CholineSmall MoleculeACHE, BCHE, CHRNA7, PCYT1A, PCYT1B, PHOSPHO1, PLD1, PLD28
DB05301LAX-101Small MoleculeCASP1, PLD12